Lipoprotein(a) is a lesser-known risk factor for heart disease that can be just as dangerous as high cholesterol. This lipoprotein can lead to plaque build-up in arteries, increasing the risk of heart attacks and strokes. It is also linked to aortic stenosis, a condition where the aortic valve narrows, restricting blood flow to the body.
Unlike cholesterol, levels of Lp(a) are determined by genetics and do not respond to traditional treatments like statins or lifestyle changes. This puts a large number of people at risk, with an estimated 1 in 5 individuals having high levels of Lp(a) and facing a higher risk of heart disease.
Recent research presented at the American Heart Association’s scientific sessions introduced two promising treatments for elevated Lp(a): an oral drug called muvalaplin and an RNA-silencing injection called zerlasiran. These treatments show potential in reducing Lp(a) levels and addressing the associated cardiovascular risks.
The Phase 2 data on these treatments, led by researchers like Steven Nissen of the Cleveland Clinic and Stephen Nicholls of Monash University, were published in JAMA, a prestigious medical journal. These studies offer hope for the millions of individuals worldwide who are at risk due to high levels of Lp(a).
As we continue to learn more about the impact of lipoprotein(a) on heart health, these new treatment options could potentially revolutionize how we approach and manage cardiovascular disease. It is essential to stay informed about these advancements in the field of cardiology to better protect our heart health and well-being.
